Nothing Special   »   [go: up one dir, main page]

BR0009176A - Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular - Google Patents

Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular

Info

Publication number
BR0009176A
BR0009176A BR0009176-6A BR0009176A BR0009176A BR 0009176 A BR0009176 A BR 0009176A BR 0009176 A BR0009176 A BR 0009176A BR 0009176 A BR0009176 A BR 0009176A
Authority
BR
Brazil
Prior art keywords
granular
formulation
active agent
stabilized
particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BR0009176-6A
Other languages
English (en)
Inventor
David F Erkoboni
Ronald S Vladyka Jr
Pamela R Stergios
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FMC Corp
Original Assignee
FMC Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FMC Corp filed Critical FMC Corp
Publication of BR0009176A publication Critical patent/BR0009176A/pt
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"PARTìCULA GRANULAR, FORMA DE DOSAGEM, MéTODOPARA PREPARAR UMA PARTìCULA GRANULAR, MISTURASECA, E, FORMULAçãO GRANULAR". Uma formulação de umagente farmaceuticamente ativo cristalino moderadamente solúvelem água em que o agente ativo é convertido e estabilizado na suaforma amorfa como uma solução sólida de um veículo normalmentehidrofóbico é descrita. O estado amorfo é estabilizado pelacomposição da formulação, fornecendo vida de prateleira longa dacomposição melhorada. Esta formulação estabilizada tambémfornece solubilidade e biodisponibilidade aumentada do agenteativo. As soluções do agente ativo são estabilizadas pelacomposição, evitando recristalização e precipitação da formacristalina menos solúvel do agente ativo das soluções aquosasdestes.
BR0009176-6A 1999-03-24 2000-03-20 Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular Pending BR0009176A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12591499P 1999-03-24 1999-03-24
US14968099P 1999-08-19 1999-08-19
US09/528,624 US6497905B1 (en) 1999-03-24 2000-03-20 Aqueous solubility pharmaceutical formulations
PCT/US2000/007298 WO2000056726A1 (en) 1999-03-24 2000-03-20 Improved aqueous solubility pharmaceutical formulations

Publications (1)

Publication Number Publication Date
BR0009176A true BR0009176A (pt) 2001-12-18

Family

ID=26824087

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009176-6A Pending BR0009176A (pt) 1999-03-24 2000-03-20 Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular

Country Status (14)

Country Link
US (3) US6497905B1 (pt)
EP (1) EP1163234B1 (pt)
JP (1) JP2003531099A (pt)
CN (1) CN1156461C (pt)
AT (1) ATE307808T1 (pt)
AU (1) AU3900300A (pt)
BR (1) BR0009176A (pt)
CA (1) CA2362728C (pt)
DE (1) DE60023465T2 (pt)
DK (1) DK1163234T3 (pt)
ES (1) ES2251985T3 (pt)
IL (2) IL145140A0 (pt)
TW (1) TWI245644B (pt)
WO (1) WO2000056726A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2381453A (en) * 1999-08-31 2003-05-07 Bradford Particle Design Ltd Active/polymer coformulations
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
CN100512798C (zh) * 2000-12-22 2009-07-15 巴克斯特国际公司 亚微米颗粒悬浮液制备方法
US6663897B2 (en) 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
US8071133B2 (en) * 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
CA2471470A1 (en) * 2002-01-08 2003-07-17 Can Technologies, Inc. Encapsulation by coating with a mixture of lipids and hydrophobic, high melting point compounds
CN101838218A (zh) 2002-02-28 2010-09-22 日本烟草产业株式会社 酯化合物及其医药用途
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US7399488B2 (en) 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
MXPA06000178A (es) * 2003-07-01 2006-04-11 Pharmacia & Upjohn Co Llc Solidos modulados en la fase de difusion.
HU227142B1 (en) * 2003-07-02 2010-08-30 Egis Gyogyszergyar Nyilvanosan Capsule of improved release containing fluconazole
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2005021486A1 (ja) 2003-08-29 2005-03-10 Japan Tobacco Inc. エステル誘導体及びその医薬用途
US7413690B1 (en) 2003-10-29 2008-08-19 The University Of Mississippi Process and apparatus for producing spherical pellets using molten solid matrices
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
KR20070004036A (ko) * 2004-04-29 2007-01-05 키스톤 리테이닝 월 시스템스, 아이엔씨 벽, 옹벽 및 그 외 유사한 것을 위한 베니어
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
PL1765292T3 (pl) 2004-06-12 2018-03-30 Collegium Pharmaceutical, Inc. Preparaty lecznicze zabezpieczające przed nadużywaniem
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
BRPI0516772A (pt) * 2004-10-25 2008-09-23 Japan Tobacco Inc formulação sólida com solubilidade e estabilidade melhoradas e método para produção da referida formulação
JP2009502807A (ja) * 2005-07-22 2009-01-29 ミリアド ジェネティクス， インコーポレイテッド 薬剤含有率の高い製剤および投与量形態
CN100430055C (zh) * 2005-11-11 2008-11-05 天津泰普药品科技发展有限公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法
JP2007308479A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
GB0818403D0 (en) * 2008-10-08 2008-11-12 Univ Leuven Kath Aqueous electrophoretic deposition
WO2010040648A2 (en) * 2008-10-06 2010-04-15 Katholieke Universiteit Leuven, K.U.Leuven R&D Functional layers of biomolecules and living cells, and a novel system to produce such
CN102307576A (zh) * 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2515879A4 (en) * 2009-12-22 2014-04-02 Fmc Corp Inc FINE PARTICLE CROSCARMELLOSIS AND USES THEREOF
EP2601973A1 (en) * 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
JP2014122328A (ja) * 2012-11-22 2014-07-03 Shin Etsu Chem Co Ltd 押出成形機又は射出成形機洗浄用組成物及び押出成形機又は射出成形機の洗浄方法
GB201602579D0 (en) 2016-02-12 2016-03-30 Mihranyan Albert New compositions
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
JP7378393B2 (ja) * 2017-11-10 2023-11-13 オースティンピーエックス リミテッド ライアビリティ カンパニー 改善された薬物製剤

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US5118799A (en) 1987-05-12 1992-06-02 Pharmacin Corporation Process for converting crystalline erythromycin ethylsuccinate into stable amorphous erythromycin ethylsuccinate
EP0462066A1 (en) 1990-06-15 1991-12-18 Warner-Lambert Company Amorphous gemfibrozil
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5208015A (en) 1991-07-23 1993-05-04 Bristol-Myers Squibb Company Topical anti-fungal agents having anti-inflammatory activity
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
DE69302897T2 (de) 1992-02-12 1996-09-26 Janssen Cilag S P A Liposomale itraconazol formulierungen
ES2158859T3 (es) 1992-03-18 2001-09-16 Janssen Pharmaceutica Nv Estereoisomeros itraconazol y saperconazol.
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IT1256386B (it) * 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
PH31594A (en) 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US5976555A (en) 1994-09-07 1999-11-02 Johnson & Johnson Consumer Products, Inc. Topical oil-in-water emulsions containing retinoids
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
CZ154398A3 (cs) 1995-11-23 1998-08-12 Janssen Pharmaceutica N.V. Pevné směsi cyklodextrinů připravené vytlačováním taveniny
US5646151A (en) 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
DK0904060T3 (da) 1996-05-20 2004-04-13 Janssen Pharmaceutica Nv Antifungale præparater med forbedret biotilgængelighed
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US6517860B1 (en) * 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
EE03904B1 (et) 1997-03-26 2002-12-16 Janssen Pharmaceutica N.V. Graanul, farmatseutiline doseerimisvorm, graanulite valmistamismeetod ja ravimiga kaetud graanulid
US5813416A (en) 1997-04-03 1998-09-29 Rudolph; James M. File with sanitizing agent
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR19990001564A (ko) 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제

Also Published As

Publication number Publication date
US6511681B2 (en) 2003-01-28
EP1163234B1 (en) 2005-10-26
US20020012706A1 (en) 2002-01-31
ES2251985T3 (es) 2006-05-16
CA2362728A1 (en) 2000-09-28
IL145140A0 (en) 2002-06-30
WO2000056726A1 (en) 2000-09-28
CN1156461C (zh) 2004-07-07
US20020037324A1 (en) 2002-03-28
EP1163234A1 (en) 2001-12-19
EP1163234A4 (en) 2003-05-02
US6379707B2 (en) 2002-04-30
DE60023465T2 (de) 2006-07-20
AU3900300A (en) 2000-10-09
TWI245644B (en) 2005-12-21
DE60023465D1 (de) 2005-12-01
CN1379768A (zh) 2002-11-13
US6497905B1 (en) 2002-12-24
CA2362728C (en) 2009-06-23
DK1163234T3 (da) 2006-02-27
IL145140A (en) 2006-08-20
JP2003531099A (ja) 2003-10-21
ATE307808T1 (de) 2005-11-15

Similar Documents

Publication Publication Date Title
BR0009176A (pt) Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular
ES2540853T3 (es) Sales de dicetopiperazina para la administración de fármacos
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
CY1120513T1 (el) Υψηλης συμπυκνωσης συνθεση μινοξιδιλης
AU2681300A (en) Solid oral dosage form containing an enhancer
CA2382098A1 (en) Sustained-release, oral pharmaceutical forms of administration
DE69927963D1 (de) Gelierbare pharmazeutische zusammensetzungen
CA2385732A1 (en) Bicyclic compounds composition and method for stabilizing the same
EA200000154A1 (ru) Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях
TR200103427T2 (tr) Integrinlerin reseptörlerine bağlanmasını engelleyen propanoik asit türevleri.
TR200000752T2 (tr) Etkin terkibin kontrollü salınımı için ilaç formülü.
EP1935417A4 (en) COMPOSITION FOR USE IN PREVENTING A HYPOGLYCEMIC STATE
MXPA02001804A (es) Composicion para inhalacion que comprende delta-9-tetrahidrocanabinol en un solvente semi-acuoso.
YU59201A (sh) Matrica koja se može direktno komprimovati, za kontrolisano oslobadjanje pojedinačnih dnevnih doza klaritromicina
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
CA2380757A1 (en) Pharmaceutical agent comprising a benzamide derivative as active ingredient
CA2525700A1 (en) S-(-)-amlodipine nicotinate and process for the preparation thereof
WO2002009717A1 (fr) Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif
EP1219296A4 (en) SEBUM PRODUCTION INHIBITORS
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
AU2001287801A1 (en) Acid-sensitive compounds, preparation and uses thereof
ATE344237T1 (de) Hydroxyacetamidobenzolsulfonamidderivate
NZ565548A (en) Stable anthelmintic veterinary formulations containing naphthalophos
EP1149832A4 (en) BENZAMIDE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM
ATE275577T1 (de) Quinapril magnesium enthaltende, pharmazeutisch wirksame zusammensetzung

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: R.P. SCHERER TECNOLOGIES, INC (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.